Xeris Biopharma Holdings, Inc. (XERS) Balance Sheet Quarterly

Xeris Biopharma Holdings, Inc.

XERS (NASDAQ)

(%)

Financials
Xeris Biopharma Holdings, Inc. Balance Sheet Statement Quarterly

Annual Quarterly

* (except for per share items) of USD

Period Ending:	2025 (Q3) 09-30	2025 (Q2) 06-30	2025 (Q1) 03-31	2024 (Q4) 12-31	2024 (Q3) 09-30	2024 (Q2) 06-30	2024 (Q1) 03-31
Report Filing:	2025-11-06	2025-08-07	2025-05-08	2025-03-06	2024-11-08	2024-08-08	1234
Total Current Assets	224	185.6	163.5	167.7	162.8	170.3	1234
Cash and Short Term Investments	91.6	59.28	58.44	71.62	69.4	77.57	1234
Cash & Equivalents	91.6	59.28	58.44	71.62	59.23	57.6	1234
Short Term Investments	0	0	0	0	10.17	19.96	1234
Receivables	53.75	53.05	46.33	40.41	41.14	42.44	1234
Inventory	67.46	67.28	52.69	48.17	45.12	42.98	1234
Other Current Assets	11.21	5.96	6.03	7.45	7.14	7.36	1234
Total Assets	370.2	334.7	315.5	323.1	321.1	331.7	1234
Total Non-Current Assets	146.2	149.1	152	155.4	158.3	161.4	1234
Property, Plant and Equipment	27.21	27.69	27.79	28.21	28.37	28.7	1234
Goodwill and Intangible Assets	113.6	116.4	119.1	121.8	124.5	127.2	1234
Goodwill	22.86	22.86	22.86	22.86	22.86	22.86	1234
Intangible Assets	90.79	93.5	96.21	98.92	101.6	104.3	1234
Long Term Investments	0	0	4.12	4.12	0	4.22	1234
Deferred Tax Assets	0	0	0	0	0	0	1234
Other Long Term Assets	5.32	5.06	0.975	1.28	5.44	1.27	1234
Total Current Liabilities	116.2	95.17	95.07	100.4	91.01	75.49	1234
Accounts Payable	6.53	9.46	6.35	2.29	7.45	5.8	1234
Notes Payable/Short Term Debt	6.19	6.16	18.08	21.18	21.1	5.31	1234
Tax Payables	0	0	0	0	0	0	1234
Deferred Revenue	0	0	0	0	0	0	1234
Other Current Liabilities	103.5	79.55	70.64	76.97	62.46	64.38	1234
Total Liabilities	371.1	354	350.6	352.7	349.4	351	1234
Total Non-Current Liabilities	254.9	258.8	255.5	252.2	258.4	275.5	1234
Total Long Term Debt	31.99	251.1	250.7	250.3	249.9	264.5	1234
Deferred Tax Liabilities Non-Current	0	0	0	0	0	3.32	1234
Deferred Revenue Non-Current	0	0	0	0	0	0	1234
Capital Lease Obligations	0	38.6	38.99	39.34	39.68	39.32	1234
Other Long Term Liabilities	222.9	-30.84	-34.15	-37.37	-31.13	-31.61	1234
Total Equity	-0.861	-19.3	-35.13	-29.61	-28.32	-19.29	1234
Non-Controlling Interest	0	0	0	0	0	0	1234
Total Stockholders' Equity	-0.861	-19.3	-35.13	-29.61	-28.32	-19.29	1234
Retained Earnings	-682.4	-683	-681.1	-671.9	-666.7	-651	1234
Accumulated Other Earnings	-0.025	-0.024	-0.025	-0.025	-0.016	-0.031	1234
Common Stock	0.017	0.016	0.016	0.015	0.015	0.015	1234
Preferred Stock	0	0	0	0	0	0	1234
Additional Paid in Capital	681.5	663.7	646	642.3	638.4	631.7	1234
Total Liabilities & Total Equity	370.2	334.7	315.5	323.1	321.1	331.7	1234
Total Liabilities & Shareholders' Equity	370.2	334.7	315.5	323.1	321.1	331.7	1234
Total Investments	0	0	4.12	4.12	10.17	24.19	1234
Total Debt	38.19	257.2	268.8	271.4	271	269.8	1234
Net Debt	-53.41	197.9	210.3	199.8	211.7	212.2	1234

Market is Open

After-Hours Quote

Market is Open

After-Hours Quote

Xeris Biopharma Holdings, Inc. Balance Sheet Statement Quarterly